Our top pick for
Heska Corporation is a diagnostics & research business based in the US. Heska Corporation shares (HSKA) are listed on the NASDAQ and all prices are listed in US Dollars. Heska Corporation employs 602 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$66.45 - $217.17|
|50-day moving average||$176.79|
|200-day moving average||$156.39|
|Wall St. target price||$208.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.47|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Heska Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Heska Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Heska Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.53. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Heska Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Heska Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11 million.
The EBITDA is a measure of a Heska Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$197.3 million|
|Operating margin TTM||0.66%|
|Gross profit TTM||$81.3 million|
|Return on assets TTM||0.25%|
|Return on equity TTM||-6.68%|
|Market capitalisation||$1.9 billion|
TTM: trailing 12 months
There are currently 307,875 Heska Corporation shares held short by investors – that's known as Heska Corporation's "short interest". This figure is 10.8% down from 345,129 last month.
There are a few different ways that this level of interest in shorting Heska Corporation shares can be evaluated.
Heska Corporation's "short interest ratio" (SIR) is the quantity of Heska Corporation shares currently shorted divided by the average quantity of Heska Corporation shares traded daily (recently around 68264.966740577). Heska Corporation's SIR currently stands at 4.51. In other words for every 100,000 Heska Corporation shares traded daily on the market, roughly 4510 shares are currently held short.
However Heska Corporation's short interest can also be evaluated against the total number of Heska Corporation shares, or, against the total number of tradable Heska Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heska Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Heska Corporation shares in existence, roughly 30 shares are currently held short) or 0.0424% of the tradable shares (for every 100,000 tradable Heska Corporation shares, roughly 42 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Heska Corporation.
Find out more about how you can short Heska Corporation stock.
We're not expecting Heska Corporation to pay a dividend over the next 12 months.
Heska Corporation's shares were split on a 1:10 basis on 29 December 2010. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heska Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Heska Corporation shares which in turn could have impacted Heska Corporation's share price.
Over the last 12 months, Heska Corporation's shares have ranged in value from as little as $66.45 up to $217.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heska Corporation's is 1.6922. This would suggest that Heska Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Additionally, the company provides a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.